Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
In today’s news reports we comment on articles dealing with: The declining rate of prostate cancer mortality in the USA Managing prostate cancer in the elderly Re-validation of the Partin tables RALP as salvage surgery for radiation-resistant patients
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: elderly, mortality rates, Partin tables, RALP, salvage | 7 Comments »
While we are all waiting for the approval of Provenge, it is worth noting that a research group at the University of Iowa has developed a very different type of prostate cancer treatment based on older technology.
Filed under: Drugs in development | Tagged: adenovirus, PSA, vaccine | 2 Comments »
There continues to be controversy over the role of testosterone replacement therapy (TRT) in men with prostate cancer who are “hypogonadal” — i.e., men with very low testosterone levels — as a consequence of their treatment.
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: testosterone replacement, TRT | 1 Comment »
In today’s news reports we comment on: The possible link between obesity and prostate cancer risk The economic impact of widespread prostate cancer screening in Europe The potential roles of tumor volume and PSMs in projecting need for adjuvant radiotherapy post-surgery Biochemical progression after treatment with degarelix (at up to 1 year)
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: adiponectin, adjuvant radiation, biochemical failure, cost, Degarelix, obesity, positive surgical margin, risk, tumor volume | Leave a Comment »
Several experts discussed current issues related to prostate cancer prevention at the annual winter meeting of the Society for Urologic Oncology in Bethesda, MD, this week.
Filed under: Diagnosis, Prevention, Risk | Tagged: dutasteride, finasteride, Prevention | 1 Comment »
In today’s news report we note new articles on: The AUA’s “best practice” statement on PSA testing Post-surgical upgrading and upstaging of low-risk prostate cancer Prostate cancer involving the rectum
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: guidelines, low risk, PSA, rectum, upgrading, upstaging | Leave a Comment »
Before the coming of the PSA test, urologists used to use serum acid phosphatase levels (usually) and serum alkaline phosphatase (S-ALP) levels (less commonly) to assess the status of men at risk for or under treatment for metastatic prostate cancer.
Filed under: Living with Prostate Cancer, Management | Tagged: Degarelix, serum alkaline phosphatase | Leave a Comment »
Also today, there are two new reports on the impact of treatment with statins (drugs like simvastatin/Zocor and atorvastatin/Lipitor) on prostate cancer risk.
Filed under: Diagnosis, Risk, Uncategorized | Tagged: risk, statin | Leave a Comment »
Three recent publications are focused on the importance of the management of complications of long-term androgen deprivation therapy (ADT) in men with progressive or more advanced forms of prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation therapy, Management, side effects | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site